|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
They were strongly immunoreactive with antiserum to prion protein but did not react with the antiserum to the amyloid A4 protein of AD.
|
2500619 |
1989 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Beta-amyloid oligomers and cellular prion protein in Alzheimer's disease.
|
19960174 |
2010 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Previous studies suggested that the cellular prion protein (PrP(c)) plays a critical role in the pathogenesis of Alzheimer's disease (AD).
|
21775587 |
2011 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Neuritic plaques characteristic of AD were once thought to be exclusively associated with beta-A4 amyloid; however, some pedigrees with familial prion disease produced neuritic plaques with PrP amyloid cores.
|
7904883 |
1993 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Earlier onset of Alzheimer's disease: risk polymorphisms within PRNP, PRND, CYP46, and APOE genes.
|
19363267 |
2009 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
By Western blotting, we found that PrP(C) overexpression down-regulated tau protein and Aβ oligomer binding alleviated the tau reduction induced by wild type but not M128V PrP(C), the high AD risk polymorphic allele in human prion gene.
|
23805846 |
2013 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Misfolded and abnormal β-sheets forms of wild-type proteins, such as cellular prion protein (PrP<sup>C</sup>) and amyloid beta (Aβ), are believed to be the vectors of neurodegenerative diseases, prion and Alzheimer's disease (AD), respectively.
|
31547531 |
2019 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this research paper, our aim is to evaluate the association between the APOE, CYP46, PRNP and PRND genes and the profile of neuropsychiatric symptoms in Polish subjects with AD and mild cognitive impairment (MCI).
|
22453181 |
2012 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recent evidence indicates that PrP(C) may play a critical role in the pathogenesis of Alzheimer disease.
|
19887909 |
2010 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Monitoring of early diagnosis of Alzheimer's disease using the cellular prion protein and poly(pyrrole-2-carboxylic acid) modified electrode.
|
29734034 |
2018 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our data demonstrated a significant 1.2-fold decrease in di-glycosylated PrP isoforms specifically in rpAD patients.
|
28671123 |
2017 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In summary, we provide further evidence for interactions of PrP(C) with proteins that are known to be the key players in AD pathogenesis.
|
24028865 |
2014 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The cell-to-cell transmission of the major pathogenic proteins of Parkinson's disease and Alzheimer's disease is reminiscent of the prion protein, which is defined as a proteinaceous infectious particle that causes human and animal transmissible spongiform encephalopathies.
|
31358351 |
2020 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that the M/V polymorphism in the PRNP gene contributes to the susceptibility of Alzheimer disease.
|
23399523 |
2013 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The initial report that cellular prion protein (PrP<sup>C</sup>) mediates toxicity of amyloid-β species linked to Alzheimer's disease was initially treated with scepticism, but growing evidence supports this claim.
|
29331212 |
2018 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
The results suggest involvement of the prion protein in the pathogenesis of early-onset AD.
|
15277640 |
2004 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This is the first report of the neuropathological changes associated with this particular abnormality of the PrP gene and it seems to demonstrate a transition between the pathology of prion disease and that of Alzheimer's disease.
|
8513392 |
1993 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Survival in Alzheimer's disease is shorter in women carrying heterozygosity at codon 129 of the PRNP gene and no APOE epsilon 4 allele.
|
18332630 |
2008 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cellular prion protein as a receptor for amyloid-β oligomers in Alzheimer's disease.
|
27639648 |
2017 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Here we investigate the capability of protein 14-3-3, total-tau (t-tau), threonin-181-phosphorylated tau (p-tau), and neuron-specific enolase (NSE) in cerebrospinal fluid (CSF) together with the prion protein gene genotype to discriminate patients with sCJD (n=21) from neurological controls (n=164) and Alzheimer's disease (AD) patients (n=49).
|
18339451 |
2009 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study reports a novel p.S17G mutation in a clinically diagnosed LOAD patient, suggesting that the PRNP mutation is present in Chinese AD patients, whereas, M129V polymorphism is not a risk factor for AD or FTD in the Chinese Han population.
|
27910931 |
2016 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although these findings do not entirely exclude a role for PrP in AD or ALS, they do not support the codon 129 genotype as a risk factor for either disease.
|
16315279 |
2005 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The interaction of PrP(C) and mGluR5 is enhanced dramatically in the brains of familial AD transgenic model mice.
|
25148681 |
2014 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Prion protein stabilizes amyloid-β (Aβ) oligomers and enhances Aβ neurotoxicity in a <i>Drosophila</i> model of Alzheimer's disease.
|
29887525 |
2018 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Fyn is an attractive target for AD therapeutics, not only based on its activation by Aβ via cellular prion protein but also due to its known interaction with tau, uniquely linking the two key pathologies in AD.
|
28709498 |
2018 |